Movement Disorders (revue) - Analysis (France)

Index « Auteurs » - entrée « Jean-Louis Montastruc »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Jean-Louis Mazurie < Jean-Louis Montastruc < Jean-Luc Dupupet  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 19.
Ident.Authors (with country if any)Title
000151 (2011) Julia Grossac [France] ; Stéphanie Ruiz [France] ; Emmanuelle Bondon-Guitton [France] ; Franck-Emmanuel Roux [France] ; Olivier Fourcade [France] ; Jean-Louis Montastruc [France] ; Thomas Geeraerts [France]Severe intracranial bleeding related to vitamin K Antagonist‐Ropinirole interaction
000177 (2011) Emmanuelle Bondon-Guitton [France] ; Santiago Perez-Lloret [France] ; Haleh Bagheri [France] ; Christine Brefel [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France
000185 (2011) Emmanuelle Bondon-Guitton [France] ; Santiago Perez-Lloret [France] ; Haleh Bagheri [France] ; Christine Brefel [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Drug-Induced Parkinsonism: A Review of 17 Years' Experience in a Regional Pharmacovigilance Center in France
000208 (2010) Jean-Louis Montastruc [France] ; Anne Charlotte Danton [France] ; Genevieve Durrieu [France] ; Isabelle Lacroix [France] ; Pascale Olivier [France] ; Agnés Sommet [France] ; Jean-Michel Senard [France]Neuropathy as a potential complication of levodopa use in Parkinson's disease: A Pharmacological and Pharmacovigilance point of view
000223 (2010) Santiago Perez-Lloret [France] ; Emmanuelle Bondon-Guitton [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Adverse drug reactions to dopamine agonists: A comparative study in the french pharmacovigilance database
000229 (2010) Santiago Perez-Lloret [France] ; Emmanuelle Bondon-Guitton [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Adverse Drug Reactions to Dopamine Agonists: A Comparative Study in the French Pharmacovigilance Database
000312 (2007) Adeline Gallini [France] ; Agnès Sommet [France] ; Anne-Marie Salandini [France] ; Patrick Veyssière [France] ; Jean-Louis Montastruc [France] ; Jean-Louis Montastruc [France]Weight‐loss associated with anti‐dementia drugs in a patient with Parkinson's disease
000401 (2005) Atul Pathak [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Jean-Michel Senard [France]Heat‐related morbidity in patients with orthostatic hypotension and primary autonomic failure
000429 (2004) Olivier Rascol [France] ; Atul Pathak [France] ; Haleh Bagheri [France] ; Jean-Louis Montastruc [France]New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance
000435 (2004) Olivier Rascol [France] ; Atul Pathak [France] ; Haleh Bagheri [France] ; Jean-Louis Montastruc [France]Dopaminagonists and fibrotic valvular heart disease: Further considerations
000457 (2003) Christine Brefel-Courbon [France] ; Karine Desboeuf [France] ; Claire Thalamas [France] ; Monique Galitzky [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Clinical and economic analysis of spa therapy in Parkinson's disease
000458 (2003) Frédéric Courbon [France] ; Christine Brefel-Courbon [France] ; Claire Thalamas [France] ; Marie Jeanne Alibelli [France] ; Isabelle Berry [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France]Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease
000463 (2003) Christine Brefel-Courbon [France] ; Karine Desboeuf [France] ; Claire Thalamas [France] ; Monique Galitzky [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Clinical and economic analysis of spa therapy in Parkinson's disease
000506 (2001) Jean-Louis Montastruc [France] ; Olivier Rascol [France]Modafinil and pramipexole‐associated somnolence
000508 (2001) Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France]Long‐term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
000518 (2000) Jean-Louis Montastruc [France]Treatment of Parkinson's disease should begin with a dopamine agonist
000552 (1999) Jean-Louis Montastruc [France] ; Marc Ziegler [France] ; Olivier Rascol [France] ; Muriel Malbezin [France]A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease
000616 (1995) Jean-Louis Montastruc [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; André Rascol [France]Does fluoxetine aggravate Parkinson's disease? A pilot prospective study
000629 (1994) Rascol [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Janet Poulik [France] ; Umberto Sabatini [France] ; Jean-Michel Senard [France] ; Michèle Ané [France] ; Jean-Louis Montastruc [France] ; André Rascol [France]Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease

List of associated KwdEn.i

Nombre de
documents
Descripteur
16Humans
9Female
9Parkinson Disease (drug therapy)
7Aged
7Male
5Antiparkinson Agents (adverse effects)
5Dopamine Agonists (adverse effects)
5Drug Therapy, Combination
5Human
5Levodopa (adverse effects)
5Middle Aged
5Parkinson disease
5Parkinson's disease
4Antiparkinson Agents (administration & dosage)
4Nervous system diseases
4Treatment Outcome
3Dopamine Agonists (administration & dosage)
3France
3Levodopa (administration & dosage)
3Pharmacovigilance
3Prospective Studies
2Adult
2Adverse Drug Reaction Reporting Systems
2Aged, 80 and over
2Antiparkinson Agents (therapeutic use)
2Antiparkinson agent
2Bromocriptine
2Bromocriptine (therapeutic use)
2Chemotherapy
2Complication
2Cross-Over Studies
2Diseases of the autonomic nervous system
2Dose-Response Relationship, Drug
2Double-Blind Method
2Drug Administration Schedule
2Heart Valve Diseases (chemically induced)
2Levodopa (therapeutic use)
2Neurologic Examination (drug effects)
2Parkinson Disease (diagnosis)
2Parkinson Disease, Secondary (chemically induced)
2Pergolide (adverse effects)
2Pilot Projects
2Ropinirole
2Time Factors
2Treatment
2adverse drug reactions
2bromocriptine
2pharmacovigilance
13-Iodobenzylguanidine (diagnostic use)
13-Iodobenzylguanidine (pharmacokinetics)
1Administration, Cutaneous
1Age Factors
1Agonist
1Analysis of Variance
1Anorexia (chemically induced)
1Antidepressant agent
1Antiparkinson Agents (pharmacology)
1Antipsychotic
1Antipsychotic Agents (adverse effects)
1Autonomic Nervous System Diseases (complications)
1Autonomic Nervous System Diseases (diagnosis)
1Autonomic Nervous System Diseases (epidemiology)
1Autonomic Nervous System Diseases (etiology)
1Autonomic Nervous System Diseases (physiopathology)
1Balneology (economics)
1Balneology (methods)
1Benzhydryl Compounds (administration & dosage)
1Benzhydryl Compounds (adverse effects)
1Benzothiazoles
1Bromocriptine (administration & dosage)
1Bromocriptine (adverse effects)
1Calcium antagonist
1Central Nervous System Stimulants (administration & dosage)
1Central Nervous System Stimulants (adverse effects)
1Cholinesterase Inhibitors (adverse effects)
1Cholinesterase Inhibitors (therapeutic use)
1Clinical trial
1Comparative study
1Cost-Benefit Analysis
1Database
1Databases, Factual
1Databases, Factual (statistics & numerical data)
1Denervation
1Differential diagnostic
1Disability Evaluation
1Disclosure
1Disorders of Excessive Somnolence (chemically induced)
1Disorders of Excessive Somnolence (drug therapy)
1Dopamine Agonists (pharmacology)
1Dopamine agonist
1Dopamine receptor
1Dyskinesia, Drug-Induced (drug therapy)
1Economic analysis
1Ergot Alkaloids (analysis)
1Ergot derivatives
1Experience
1Fibrosis (chemically induced)
1Fluoxetine (administration & dosage)
1Fluoxetine (adverse effects)
1Follow-Up Studies

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Jean-Louis Montastruc" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Jean-Louis Montastruc" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Jean-Louis Montastruc
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024